Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
This phase I trial is studying the side effects and best dose of giving ridaforolimus and vorinostat together in treating patients with advanced solid tumors or lymphoma. Giving ridaforolimus in combination with vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Unspecified Adult Solid Tumor, Protocol Specific
Other: pharmacological study
Other: laboratory biomarker analysis
|Study Design:||Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Solid Tumors or Lymphoma (IND 109130)|
- Safety and tolerability of study treatment [ Time Frame: First 3 weeks of treatment ] [ Designated as safety issue: Yes ]Assessed by National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 4.0.
- Progression free survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]Kaplan Meier curves will be used. Proportions, 95% confidence intervals, and cumulative incidence curves will be used to characterize response rates.
|Study Start Date:||October 2010|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Experimental: Treatment (ridaforolimus and vorinostat)
Patients receive ridaforolimus PO once daily on days 1-5 and vorinostat PO twice daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Other Names:Drug: vorinostat
Other Names:Procedure: biopsy
Optional correlative studies
Other Name: biopsiesOther: pharmacological study
Other Name: pharmacological studiesOther: laboratory biomarker analysis
I. To determine which dose combinations of Ridaforolimus and Vorinostat are safe and tolerable.
II. To define the maximum tolerated dose. III. To characterize dose limiting toxicities.
I. To describe the activity of this combination amongst all enrolled patients in terms of response rate, progression free survival and overall survival.
II. To describe the activity of this combination in the subset of patients with RCC in terms of response rate, progression free survival and overall survival.
III. To describe the pharmacodynamic effects of these agents in combination.
OUTLINE: This is a dose escalation study.
Patients receive ridaforolimus orally (PO) once daily on days 1-5 and vorinostat PO twice daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every three months for up to 3 years.
|United States, Pennsylvania|
|Fox Chase Cancer Center|
|Rockledge, Pennsylvania, United States, 19046|
|Principal Investigator:||Elizabeth Plimack||Fox Chase Cancer Center|